Videx (didanosine)
Company: Bristol-Myers Squibb
Approval Status: Approved June 1996
Treatment for: HIV infection
Areas: Immunology/Infectious Diseases
| General Information | Clinical Results | Mechanism of Action |
General Information
A smaller dosage of Videx has been approved for the treatment of HIV infection in adults and children when antiretroviral therapy is warranted. The new Videx tablet is 35% smaller than the original tablet. In addition, the taste has been improved with a mandarin orange flavor. The new Videx tablets will be manufactured in 25 mg, 50 mg, 100 mg, and 150 mg tablets. The new tablet will be available immediately.
Clinical Results
Recent results from four large-scale clinical trials show that Vide; either alone or in combination, delays the onset of AIDS and improves survival.
Mechanism of Action
Videx belongs to a class of drugs known as nucleoside analogs. It works by inhibiting reverse transcriptase, an enzyme required for replication of HIV.
The FDA drug information shown here is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.
